Adma Biologics Inc (NASDAQ: ADMA) started the day on Wednesday, with a price increase of 0.15% at $19.95, before settling in for the price of $19.92 at the close. Taking a more long-term approach, ADMA posted a 52-week range of $3.60-$23.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 73.26%. Meanwhile, its Annual Earning per share during the time was 38.68%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 494.23%. This publicly-traded company’s shares outstanding now amounts to $236.38 million, simultaneously with a float of $228.45 million. The organization now has a market capitalization sitting at $4.72 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.05, while the 200-day Moving Average is $12.79.
Adma Biologics Inc (ADMA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Adma Biologics Inc’s current insider ownership accounts for 3.36%, in contrast to 88.42% institutional ownership. According to the most recent insider trade that took place on Nov 22 ’24, this organization’s CFO and Treasurer sold 15,000 shares at the rate of 21.15, making the entire transaction reach 317,250 in total value, affecting insider ownership by 199,433. Preceding that transaction, on Nov 22 ’24, Company’s President and CEO sold 48,967 for 21.10, making the whole transaction’s value amount to 1,033,204. This particular insider is now the holder of 1,989,007 in total.
Adma Biologics Inc (ADMA) Earnings and Revenue Records
Adma Biologics Inc’s EPS increase for this current 12-month fiscal period is 494.23% and is forecasted to reach 0.73 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 20.00% through the next 5 years, which can be compared against the 38.68% growth it accomplished over the previous five years trading on the market.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Let’s observe the current performance indicators for Adma Biologics Inc (ADMA). It’s Quick Ratio in the last reported quarter now stands at 3.26. The Stock has managed to achieve an average true range (ATR) of 1.06. Alongside those numbers, its PE Ratio stands at $72.20, and its Beta score is 0.73. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 12.32. Similarly, its price to free cash flow for trailing twelve months is now 59.40.
In the same vein, ADMA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.28, a figure that is expected to reach 0.15 in the next quarter, and analysts are predicting that it will be 0.73 at the market close of one year from today.
Technical Analysis of Adma Biologics Inc (ADMA)
If we take a close look at the recent performances of Adma Biologics Inc (NASDAQ: ADMA), its last 5-days Average volume was 3.29 million that shows plunge from its year to date volume of 3.62 million. During the previous 9 days, stock’s Stochastic %D was recorded 38.35% While, its Average True Range was 1.04.
Raw Stochastic average of Adma Biologics Inc (ADMA) in the period of the previous 100 days is set at 72.52%, which indicates a major rise in contrast to 40.90% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 59.15% that was lower than 78.64% volatility it exhibited in the past 100-days period.
